Table 1.
Association Between Clinicopathologic Variables and DHRS9 Expression in the Two Datasets
| Variables | DHRS9 in the Jiaxing Dataset (IHC) | DHRS9 in the TCGA Dataset (mRNA) | ||||
|---|---|---|---|---|---|---|
| High (n = 75) | Low (n = 24) | P value | High (n = 89) | Low (n = 89) | P value | |
| Age (years) | 66 [39, 82] | 64.5 [41, 80] | 0.47 | 65 [35, 88] | 65 [39, 81] | 1 |
| Sex | 0.59 | 0.29 | ||||
| Male | 37 (49.3%) | 14 (58.3%) | 53 (59.6%) | 45 (50.6%) | ||
| Female | 38 (50.7%) | 10 (41.7%) | 36 (40.4%) | 44 (49.4%) | ||
| Site | 0.30 | 0.85 | ||||
| Head | 57 (76.0%) | 15 (62.5%) | 74 (83.1%) | 72 (80.9%) | ||
| Body and tail | 18 (24.0%) | 9 (37.5%) | 15 (16.9%) | 17 (19.1%) | ||
| Tumor size(cm) | 3.5 [1.2, 9.0] | 3.1 [1.5, 8.0] | 0.24 | 3.8 [0.3, 12.0] | 3.2 [1.3, 14.0] | 0.12 |
| Vascular infiltration | 0.04* | |||||
| Absent | 51 (68.0%) | 22 (91.7%) | ||||
| Present | 24 (32.0%) | 2 (8.3%) | ||||
| Nerve infiltration | 1 | |||||
| Absent | 17 (22.7%) | 6 (25.0%) | ||||
| Present | 58 (77.3%) | 18 (75.0%) | ||||
| Grade | 1 | 0.05 | ||||
| Well | 33 (44.0%) | 11 (45.8%) | 10 (11.2%) | 21 (23.6%) | ||
| Poor | 42 (56.0%) | 13 (54.2%) | 79 (88.8%) | 68 (76.4%) | ||
| T stage | 0.46 | 0.63 | ||||
| T1+T2 | 48 (64.0%) | 18 (75.0%) | 58 (65.2%) | 62 (69.7%) | ||
| T3+T4 | 27 (36.0%) | 6 (25.0%) | 31 (34.8%) | 27 (30.3%) | ||
| LNM | 0.11 | 0.25 | ||||
| Absent | 31 (41.3%) | 15 (62.5%) | 22 (24.7%) | 30 (33.7%) | ||
| Present | 44 (58.7%) | 9 (37.5%) | 67 (75.3%) | 59 (66.3%) | ||
| AJCC stage | 1 | 1 | ||||
| I+II | 60 (80.0%) | 19 (79.2%) | 59 (66.3%) | 60 (67.4%) | ||
| III+IV | 15 (20.0%) | 5 (20.8%) | 30 (33.7%) | 29 (32.6%) | ||
Note: *P < 0.05.
Abbreviations: AJCC, American Joint Committee on Cancer; DHRS9, dehydrogenase/reductase member 9; IHC, immunohistochemistry; LNM, lymph node metastasis; T stage, “tumor” attributes in 8th edition TNM classification; TCGA, The Cancer Genome Atlas.